ArticleGenes & genomics2019
Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Article in Genes & genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- In silico pathway-based subtractive proteomics for identifying novel drug targets in Candida albicans with structure-guided drug repurposing of aspartate-semialdehyde dehydrogenase inhibitors.Journal of molecular modeling · 2026Article
- From genome to drug targets: computational subtractive genomics reveals novel anti-filarial targets in Wuchereria bancrofti and identifies plant-based inhibitors of β-1,4-mannosyltransferase, a high-priority target.Molecular diversity · 2026Article
- Constraints in temperature adaptation reinforce differences in thermal niche between mesophilic and psychrotolerantProceedings. Biological sciences · 2025Article
- In silico discovery of druggable targets in Citrobacter koseri using echinoderm metabolites and molecular dynamics simulation.Scientific reports · 2024Article
- Comparative Proteomics and Genome-Wide Druggability Analyses Prioritized Promising Therapeutic Targets against Drug-ResistantMicroorganisms · 2023Article
- Article
- Identification of Putative Vaccine and Drug Targets against the Methicillin-ResistantMolecules (Basel, Switzerland) · 2022Article
- Subtractive genomics profiling for potential drug targets identification against Moraxella catarrhalis.PloS one · 2022Article
- Prediction of Potential Drug Targets and Vaccine Candidates Against Antibiotic-ResistantInternational journal of peptide research and therapeutics · 2022Article
- Hypothetical protein FoDbp40 influences the growth and virulence ofFrontiers in microbiology · 2022Article
- In Silico Core Proteomics and Molecular Docking Approaches for the Identification of Novel Inhibitors againstInternational journal of environmental research and public health · 2021Article
- Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets inPathogens (Basel, Switzerland) · 2021Article
- Article
- Cinnamaldehyde inhibits the growth ofPeerJ · 2021Article
- Comparative Metabolic Pathways Analysis and Subtractive Genomics Profiling to Prioritize Potential Drug Targets AgainstFrontiers in microbiology · 2021Article
- In Silico Subtractive Proteomics Approach for Identification of Potential Drug Targets inInternational journal of environmental research and public health · 2020Article
- A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori.Genes & genomics · 2020Article
- Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era.Frontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong the resistant isolates of MTB, multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) have been the areas of growing concern. The genomic analysis showed that the respective genomic pool of the XDR-MTB proteome contains more than 30% of the hypothetical proteins for which no functions have been annotated yet. This class of proteins presumably have their own importance to complete genome and proteome information. The bioinformatics advancements have helped to annotate those hypothetical proteins by using various computational tools and have potential to classify them functionally.
objectiveThe objective of this study was to propose a new and unique drug target against the deadly Mycobacterium tuberculosis using Bioinformatics approaches to characterize the hypothetical proteins.
resultsWe stepwise reduced the hypothetical proteins (total number: 1256) out of the complete proteome to only 26 essential hypothetical proteins. Out of those 26 proteins, the protein WP_003401246.1 was computationally characterized as the druggable target.
conclusionThe study proposed a hypothetical protein from complete proteome of the XDR-MTB as a new drug target against which new drug candidates can be proposed. Hence, the study opens up the new avenues in the areas of drug discovery against deadly M. tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.